What are the most common side effects of infliximab?

Infliximab, also known under the Remicade® brand, can cause a number of different side effects. Common side effects may include headache, nausea, diarrhea, abdominal pain and localized redness and swelling. Patients taking a drug may have the reactivation of infections that lay sleeping in the body, such as tuberculosis or hepatitis. They are also endangered by infection by other viruses, bacteria or fungi obtained from the environment. Infliximab side effects may include a decrease in patient blood and the development of various cancer. These symptoms are usually mild. They may include headache, nausea, diarrhea, abdominal pain, cough and joint pain. Some patients have located redness or swelling at the site of infusion. These symptoms often improve over time and are not a reason to stop medication treatment.

Multi -saler infliximab side effects may include reactivation of latent diseases already in patients. This may happen because the drug suppresses the immune system. Tuberculosis (TB)A hepatitis B are infections that are most often repeated after this drug start. For this reason, patients are tested for TBS or hepatitis infection before this therapeutic regime. After the infliximab is started, the annual protein purified derivative (PPD) is administered on TB to monitor the ongoing TB exposure.

If the drug reduces the activity of the immune system, some other types of infliximab side effects may also occur. Patients are exposed to increased risk of new infections. Some of these infections - such as upper respiratory tract infections, sinusitis and urinary tract infections - can be mild and either determination without treatment or are easy to antibiotics. However, other infections are more serious. Some pathological organisms, such as fungi, focus on patients with reduced immune function and can cause significant complications.

rarely can infliximaB cause a reduction in the number of blood blood. Red blood cells, white blood cells and plates may decrease due to the use of the drug. A reduced number of these cells can cause severe side effects and may even be life -threatening in some cases. For this reason, patients are regularly checked for inflixamab therapy to monitor decreasing trends.

ongoing infliximab treatment can also expose patients the risk of developing certain cancers later in life. The most common malignancies observed in patients are lymphomas, either from Hodgkin or non-hodgkin type. Due to the drug to treat inflammatory bowel disease, they are exposed to an increased risk of developing hepatosplenic T-cell lymphoma. Some studies have also been shown to be a highly incidence of non -semanoma skin in patients taking drugs.